Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 3
2012 1
2013 2
2015 1
2016 4
2017 1
2018 4
2019 11
2020 9
2021 2
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Bias reduction using combined stain normalization and augmentation for AI-based classification of histological images.
Franchet C, Schwob R, Bataillon G, Syrykh C, Péricart S, Frenois FX, Penault-Llorca F, Lacroix-Triki M, Arnould L, Lemonnier J, Alliot JM, Filleron T, Brousset P. Franchet C, et al. Among authors: lemonnier j. Comput Biol Med. 2024 Mar;171:108130. doi: 10.1016/j.compbiomed.2024.108130. Epub 2024 Feb 8. Comput Biol Med. 2024. PMID: 38387381
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J, Weder P, Ribi K, Thürlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, Müller A, Membrez-Antonioli V, Gérard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H; Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Huober J, et al. Among authors: lemonnier j. JAMA Oncol. 2023 Oct 1;9(10):1381-1389. doi: 10.1001/jamaoncol.2023.2909. JAMA Oncol. 2023. PMID: 37561451
Economic evaluation and budget-impact of accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation (WBI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial.
Le Bras A, Belkacemi Y, Bourgier C, Gabelle-Flandin I, Petit A, Guilbert P, Geffrelot J, Racadot S, Rivin Del Campo E, Hanzen C, Charra Brunaud C, Auzac G, Lacornerie T, Lemonnier J, Lartigau E, Durand-Zaleski I. Le Bras A, et al. Among authors: lemonnier j. Radiother Oncol. 2023 Oct;187:109818. doi: 10.1016/j.radonc.2023.109818. Epub 2023 Jul 20. Radiother Oncol. 2023. PMID: 37480995 Clinical Trial.
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Rassy E, Filleron T, Viansone A, Lacroix-Triki M, Rivera S, Desmoulins I, Serin D, Canon JL, Campone M, Gonçalves A, Levy C, Cottu P, Petit T, Eymard JC, Debled M, Bachelot T, Dalenc F, Roca L, Lemonnier J, Delaloge S, Pistilli B. Rassy E, et al. Among authors: lemonnier j. Breast Cancer Res Treat. 2023 Jun;199(2):371-379. doi: 10.1007/s10549-023-06912-4. Epub 2023 Mar 29. Breast Cancer Res Treat. 2023. PMID: 36988749
Baseline quality of life and chemotherapy toxicities in patients with early breast cancer.
Licaj I, Coquan E, Dabakuyo-Yonli TS, Dauchy S, Vaz Luis I, Charles C, Lemogne C, Tredan O, Vanlemmens L, Jouannaud C, Levy C, Rigal O, Fournier M, Petit T, Dalenc F, Rouanet P, Lemonnier J, Everhard S, Cottu P, Joly F. Licaj I, et al. Among authors: lemonnier j. Cancer. 2023 Apr 1;129(7):1085-1095. doi: 10.1002/cncr.34643. Epub 2023 Jan 15. Cancer. 2023. PMID: 36642837 Free article.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Among authors: lemonnier j. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Bachelot T, Cottu P, Chabaud S, Dalenc F, Allouache D, Delaloge S, Jacquin JP, Grenier J, Venat Bouvet L, Jegannathen A, Campone M, Del Piano F, Debled M, Hardy-Bessard AC, Giacchetti S, Mouret-Reynier MA, Barthelemy P, Kaluzinski L, Mailliez A, Legouffe E, Sephton M, Bliss J, Canon JL, Penault-Llorca F, Lemonnier J, Cameron D, Andre F. Bachelot T, et al. Among authors: lemonnier j. J Clin Oncol. 2022 Nov 10;40(32):3699-3708. doi: 10.1200/JCO.21.02179. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605174 Clinical Trial.
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.
Delaloge S, Dureau S, D'Hondt V, Desmoulins I, Heudel PE, Duhoux FP, Levy C, Lerebours F, Mouret-Reynier MA, Dalenc F, Frenel JS, Jouannaud C, Venat-Bouvet L, Nguyen S, Callens C, Gentien D, Rapinat A, Manduzio H, Vincent-Salomon A, Lemonnier J, Cottu P; French Breast cancer Intergroup Unicancer-UCBG. Delaloge S, et al. Among authors: lemonnier j. Eur J Cancer. 2022 May;166:300-308. doi: 10.1016/j.ejca.2022.01.014. Epub 2022 Mar 22. Eur J Cancer. 2022. PMID: 35337692 Clinical Trial.
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F, Marce M, Delaloge S, Hardy-Bessard AC, Bachelot T, Bièche I, Pradines A, De La Motte Rouge T, Canon JL, André F, Arnould L, Clatot F, Lemonnier J, Marques S, Bidard FC; PADA-1 investigators. Berger F, et al. Among authors: lemonnier j. BMJ Open. 2022 Mar 3;12(3):e055821. doi: 10.1136/bmjopen-2021-055821. BMJ Open. 2022. PMID: 35241469 Free PMC article. Clinical Trial.
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.
Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart M, Roblin E, Michiels S. Loi S, et al. Among authors: lemonnier j. NPJ Breast Cancer. 2022 Jan 11;8(1):3. doi: 10.1038/s41523-021-00362-1. NPJ Breast Cancer. 2022. PMID: 35017545 Free PMC article.
43 results